Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Chemomab Therapeutics (CMMB – Research Report), Fate Therapeutics (FATE – Research Report) and Disc Medicine (IRON – Research Report).

Chemomab Therapeutics (CMMB)

Oppenheimer analyst Jeff Jones maintained a Buy rating on Chemomab Therapeutics today and set a price target of $6.00. The company’s shares closed last Thursday at $0.81.

According to TipRanks.com, Jones is a 5-star analyst with an average return of 29.3% and a 41.6% success rate. Jones covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, AN2 Therapeutics, Inc., and Fusion Pharmaceuticals.

Chemomab Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

See today’s best-performing stocks on TipRanks >>

Fate Therapeutics (FATE)

In a report released yesterday, Etzer Darout from BMO Capital initiated coverage with a Hold rating on Fate Therapeutics and a price target of $6.00. The company’s shares closed last Thursday at $3.90.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 37.2% and a 54.5% success rate. Darout covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Arvinas Holding Company, and Terns Pharmaceuticals.

Fate Therapeutics has an analyst consensus of Hold, with a price target consensus of $6.64, which is a 76.1% upside from current levels. In a report issued on May 6, Wedbush also maintained a Hold rating on the stock with a $7.00 price target.

Disc Medicine (IRON)

BMO Capital analyst Evan Seigerman maintained a Buy rating on Disc Medicine yesterday and set a price target of $50.00. The company’s shares closed last Thursday at $30.77, close to its 52-week low of $25.60.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 3.8% and a 45.5% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Bristol-Myers Squibb, and AbCellera Biologics.

Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $53.63, implying an 86.7% upside from current levels. In a report released today, LifeSci Capital also maintained a Buy rating on the stock with a $48.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CMMB:

• Chemomab Advances PSC Trial with Promising Outlook
• Chemomab Therapeutics reports Q1 EPS (1c) vs. (4c) last year
• Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
• Chemomab Therapeutics Receives Nasdaq Extension
• Chemomab Therapeutics granted 180-day extension to regain Nasdaq compliance